Abstract
Gemcitabine has been evaluated in combination with paclitaxel, docetaxel, anthracyclines, vinorelbine, and cisplatin as first-line treatment and after prior chemotherapy in patients with metastatic breast cancer. Results with gemcitabine/taxane combinations have been especially encouraging, with these combinations providing promising outcomes with regard both to tumor response and tolerability. The combination of gemcitabine and paclitaxel has garnered particular interest for further phase III evaluation on the basis of high response rates and durable responses in both treatment-naive and treatment-experienced patients, including anthracycline-pretreated patients.
MeSH terms
-
Anthracyclines / administration & dosage
-
Antimetabolites, Antineoplastic / administration & dosage*
-
Antineoplastic Agents, Phytogenic / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / pathology
-
Cisplatin / administration & dosage
-
Clinical Trials, Phase II as Topic
-
Deoxycytidine / administration & dosage*
-
Deoxycytidine / analogs & derivatives*
-
Docetaxel
-
Drug Administration Schedule
-
Female
-
Gemcitabine
-
Humans
-
Neoplasm Metastasis
-
Paclitaxel / administration & dosage
-
Taxoids / administration & dosage
-
Vinblastine / administration & dosage
-
Vinblastine / analogs & derivatives*
-
Vinorelbine
Substances
-
Anthracyclines
-
Antimetabolites, Antineoplastic
-
Antineoplastic Agents, Phytogenic
-
Taxoids
-
Deoxycytidine
-
Docetaxel
-
Vinblastine
-
Paclitaxel
-
Cisplatin
-
Vinorelbine
-
Gemcitabine